

WD 16246
PATENT
Box 5eq
Attorney Docket No. 3890US

CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)

I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service

- ☒ as first class mail, postage prepaid (37 C.F.R. § 1.8)
☐ "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10
Express mail label mailing number:

on the enclosed inserted below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Eric Eliason

Typed name of person mailing transmittal

July 20, 2000

Date of Deposit

Signature of person mailing transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: D. Romeo

Group Art Unit No.: 1646

Applicant(s): Van Leengood et al.

Filing date: April 30, 1999

Serial No.: 09/202,104

For (title): IL-6 AND IL-6-RECEPTOR DERIVED PEPTIDE HAVING
IL-6 ANTAGONISTIC OR AGONISTIC ACTIVITY

COMMUNICATION TRANSMITTAL

RECEIVED
JUL 31 2000
TECH CENTER 1600/2900

RECEIVED
JUL 26 2000
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

- ☒ Postcard receipt acknowledgment (attached to the front of this transmittal).
☒ Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fees may be charged to deposit account no. 20-1469.
☐ Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.
☐ Preliminary amendment.
☒ Amendment or other communication in response to the notice to comply mailed June 20, 2000.
☐ Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed.
☐ Petition for Extension of Time in duplicate with check no. in the amount of \$.
☐ Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of).
☐ Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.
☒ Copy of notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures; Statement under 37 C.F.R. §§ 1.821 and 1.825; Paper copy of sequence listing; and CRF copy of sequence listing.

Remarks:

- ☐ An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

	1	2	3	EXTRA
Total claims	-	=	x 18.00 =	
Indep. claims	-	=	x 78.00 =	
First presentation of a multiple dep. claim (+260.00)				
SUBTOTAL				
Reduction for small entity - 50% of subtotal*				
TOTAL ADDITIONAL FEE (subtotal minus any reduction)				

*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

- 1 Claims remaining after amendment.
- 2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.
- 3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

- ☒ The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.

Respectfully submitted,

Edgar R. Cataxinos

Edgar R. Cataxinos
Reg. No. 39,391
TRASK, BRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550
(801) 532-1922

Date: July 20, 2000
Enclosures: As identified above

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial ~~or substitute~~ paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



PATENT
3890US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Van Leengoed et al.

Serial No.: 09/202,104

Filed: April 30, 1999

For: IL-6 AND IL-6-RECEPTOR
DERIVED PEPTIDE HAVING IL-6
ANTAGONISTIC OR AGONISTIC
ACTIVITY

Examiner: D. Romeo

Group Art Unit: 1646

Attorney Docket No.: 3890US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

7-20-2000
Date of Deposit

Lynette Eliason
Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Lynette Eliason
Typed/printed name of person whose signature is contained above

STATEMENT UNDER 37 C.F.R. §§ 1.821 through 1.825

Commissioner for Patents
Washington, D.C. 20231

Sir:


I, Edgar R. Cataxinos, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), have been corrected to comply with the requirements of 37 C.F.R. § 1.822.

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be the same as the paper copy of the substitute SEQUENCE LISTING.

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,



Edgar R. Cataxinos
Registration No. 39,931
Attorney for Applicants
TRASK, BRITT
P. O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: July 20, 2000

N:\2183\3890\Sequence listing statement.wpd